Epidemiology of norovirus disease in the first 2 years of life: A prospective multisite cohort study in Lima, Peru.

Autor:	Lanata CF; Instituto de Investigación Nutricional, Lima, Perú; Department of Pediatrics, Vanderbilt University, Nashville, TN, USA., Soto G; Clinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Perú., Gil AI; Instituto de Investigación Nutricional, Lima, Perú., Neyra J; Clinical Trials Unit, U.S. Naval Medical Research Unit SOUTH (NAMRU SOUTH), Lima, Perú., Cornejo R; Instituto de Investigación Nutricional, Lima, Perú., Romero C; Vysnova Partners, LLC, Lima, Perú., Ecker L; Instituto de Investigación Nutricional, Lima, Perú., Huaylinos ML; Instituto de Investigación Nutricional, Lima, Perú., La Rosa S; Vysnova Partners, LLC, Lima, Perú., Goios A; P95 Epidemiology and Pharmacovigilance, Leuven, Belgium., Borkowski A; HilleVax, Inc., Boston, USA., Weil J; Takeda Pharmaceuticals International AG, Zürich, Switzerland. Electronic address: John.Weil@takeda.com.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Nov 21; Vol. 150, pp. 107308. Date of Electronic Publication: 2024 Nov 21.
DOI:	10.1016/j.ijid.2024.107308
Abstrakt:	Objectives: Norovirus is associated with 18% of acute gastroenteritis (AGE) cases worldwide. We aim to document the norovirus-related AGE incidence in peri-urban areas of Lima (Peru), evaluating the potential impact of a norovirus vaccine introduction. Methods: A prospective, community-based pediatric cohort study was established at two sites in Lima. Healthy children between 5 and 18 months were contacted weekly for AGE detection during a 6-month period. Stool samples from AGE cases were tested for norovirus by RT-PCR. Incidence and coinfection of norovirus-associated AGE were analyzed. All norovirus-positive samples were genotyped by Sanger DNA sequencing. Results: Among 498 enrolled children, 461 (93%) completed the follow-up period. We detected 799 AGE cases, yielding 676 valid stool samples. Norovirus was detected in 216 samples (32%), with an incidence of 7.7 episodes per 100 child-months (95% CI: 6.7-8.8). Genotypes GII.4 (31%) and GII.6 (22%) were frequent. Campylobacter (43%) and Salmonella spp. (15%) were the most common coinfections with norovirus. Ninety-five percent of study children had received an oral rotavirus vaccine. Conclusion: Norovirus was the second most frequent cause of AGE in this Peruvian cohort with high rotavirus vaccine coverage. An effective norovirus vaccine would have an important public health benefit in this population. Competing Interests: Declarations of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Claudio F. Lanata, Ana I. Gil, Rubelio Cornejo, and Lucie Ecker declare that they received research grant funding to their Institute from Takeda Vaccines Inc. and HilleVax Inc. to conduct this norovirus epidemiology study and to conduct a Phase IIb norovirus vaccine trial. John Weil is an employee of Takeda Pharmaceuticals International AG. Astrid Borkowski is an employee of HilleVax Inc. Giselle Soto and Joan Neyra are employees of the U.S. Government. Ana Goios is an employee of P95 Epidemiology and Pharmacovigilance, which received funding from Takeda Vaccines Inc. and HilleVax Inc. in connection with the conduct of this study. All remaining authors have declared no conflicts of interest. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu